Michael Reth News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael reth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Reth Today - Breaking & Trending Today

Researchers discover new structures on the surface of living B cells for the first time

Using new microscopic methods in combination with machine learning-based image analysis, researchers from Freiburg have discovered new structures on the surface of living B cells that affect the distribution and possibly the function of their antigen receptors. ....

Deniz Saltukoglu , Ralf Reski , Michael Reth , Emily Henderson , Freiburg University , University Of Osnabr , University Of Freiburg , Centre For Integrative Biological Signalling , Integrative Biological Signalling Studies , Industry Focus , B Cell , Immune System , Living Cells , Machine Learning ,

Findings can inform vaccines, treatments for COVID, cancers, and beyond

Findings can inform vaccines, treatments for COVID, cancers, and beyond
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United States , Chao Wu , Lying Dong , Frederick Alt , Jianying Yang , Deniz Saltukoglu , Charlesa Janeway , Frauke Bartels Burgahn , Zhuoyi Liang , Michael Reth , Department Of Biological Chemistry , University Of Freiburg , National Institutes Of Health , Harvard Medical School , Researchers At Harvard Medical School , Freiberg University , Program In Cellular , German Research Foundation , University Of Freiberg , Harvard Center , Blavatnik Institute , Boston Children , Patricia Springer Professor , Structural Biology , Molecular Medicine , Biological Chemistry ,

Anti-cancer drug's mode of operation deciphered

E-Mail
IMAGE: Freiburg researchers investigate how the membrane protein CD20 organizes the nanostructures on the B cell membrane.
view more
Credit: Illustration: Julia Jullesova
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients to investigate how CD20 organizes the nanostructures on the B cell membrane. If the protein is missing or Rituximab binds to it, the organization of the B cell surface changes. The resting B cell is activated in the process. The team has published the research in the journal ....

Michael Reth , University Of Freiburg , Institute Of Biology , Centre For Biological Signalling Studies He , National Academy Of Science , Centre For Integrative Biological Signalling , National Academy , Molecular Immunology , Integrative Biological Signalling , Cell Biology , Medicine Health , மைக்கேல் ரெத் , நிறுவனம் ஆஃப் உயிரியல் , தேசிய கலைக்கழகம் ஆஃப் அறிவியல் , தேசிய கலைக்கழகம் , மூலக்கூறு நோயெதிர்ப்பு , செல் உயிரியல் , மருந்து ஆரோக்கியம் ,